Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11β-hydroxysteroid dehydrogenases in multiple sclerosis: Implications for lesion pathogenesis

Brain, Behavior, and Immunity

Volumn 24, Issue 6, 2010, Pages 975-984

  Heidbrink, Claudia ^a   Häusler, Sebastian F M ^a   Buttmann, Mathias ^a   Ossadnik, Monika ^a   Strik, Herwig M ^b   Keller, Andreas ^c   Buck, Dorothea ^a,b,g   Verbraak, Evert ^d   van Meurs, Marjan ^d   Krockenberger, Mathias ^a   Mehling, Matthias ^e   Mittelbronn, Michel ^f   Laman, Jon D ^d   Wiendl, Heinz ^a   Wischhusen, Jörg ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Biomarker Discovery Center Heidelberg   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f GOETHE UNIVERSITY   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

11 Hydroxysteroid dehydrogenase 1 2; Cerebrospinal fluid; Cortisol; Glucocorticoids; Macrophages; Multiple sclerosis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; CORTISONE; HYDROCORTISONE; MESSENGER RNA; MYELIN; PRASTERONE; 11BETA HYDROXYSTEROID DEHYDROGENASE; MYELIN PROTEIN;

ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CEREBROSPINAL FLUID CYTOLOGY; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY DISEASE; MACROPHAGE; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; BLOOD; BRAIN; CELL COUNT; CEREBROSPINAL FLUID; ENZYMOLOGY; FOAM CELL; PATHOLOGY; PHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; 11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADULT; BRAIN; CELL COUNT; DEHYDROEPIANDROSTERONE; FEMALE; FOAM CELLS; GENE EXPRESSION; HUMANS; HYDROCORTISONE; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MULTIPLE SCLEROSIS; MYELIN PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77954213298     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2010.04.003     Document Type: Article

References (51)

1. Alikhani-Koupaei R., Fouladkou F., Fustier P., Cenni B., Sharma A.M., Deter H.C., Frey B.M., Frey F.J. Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J. 2007, 21:3618-3628.
2. Azuma T., Matsubara T., Shima Y., Haeno S., Fujimoto T., Tone K., Shibata N., Sakoda S. Neurosteroids in cerebrospinal fluid in neurologic disorders. J. Neurol. Sci. 1993, 120:87-92.
3. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001, 125:279-284.
4. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J. Exp. Med. 1991, 174:1549-1555.
5. Boven L.A., Van Meurs M., Van Zwam M., Wierenga-Wolf A., Hintzen R.Q., Boot R.G., Aerts J.M., Amor S., Nieuwenhuis E.E., Laman J.D. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 2006, 129:517-526.
6. Brown R.C., Han Z., Cascio C., Papadopoulos V. Oxidative stress-mediated DHEA formation in Alzheimer's disease pathology. Neurobiol. Aging 2003, 24:57-65.
7. Chapman K.E., Gilmour J.S., Coutinho A.E., Savill J.S., Seckl J.R. 11Beta-hydroxysteroid dehydrogenase type 1 - a role in inflammation?. Mol. Cell. Endocrinol. 2006, 248:3-8.
8. Cohen J.A., Imrey P.B., Calabresi P.A., Edwards K.R., Eickenhorst T., Felton W.L., Fisher E., Fox R.J., Goodman A.D., Hara-Cleaver C., Hutton G.J., Mandell B.F., Scott T.F., Zhang H., Apperson-Hansen C., Beck G.J., Houghtaling P.L., Karafa M.T., Stadtler M. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009, 72:535-541.
9. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
10. Conway D., Cohen J.A. Combination therapy in multiple sclerosis. Lancet Neurol. 2010, 9:299-308.
11. Dhillo W.S., Kong W.M., Le Roux C.W., Alaghband-Zadeh J., Jones J., Carter G., Mendoza N., Meeran K., O'Shea D. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. Eur. J. Endocrinol. 2002, 146:231-235.
12. Du C., Khalil M.W., Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J. Immunol. 2001, 167:7094-7101.
13. Erkut Z.A., Endert E., Huitinga I., Swaab D.F. Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis. Mult. Scler. 2002, 8:229-236.
14. Fassbender K., Schmidt R., Mössner R., Kischka U., Kühnen J., Schwartz A., Hennerici M. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch. Neurol. 1998, 55:66-72.
15. Geurts J.J., Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008, 7:841-851.
16. Gilmour J.S., Coutinho A.E., Cailhier J.F., Man T.Y., Clay M., Thomas G., Harris H.J., Mullins J.J., Seckl J.R., Savill J.S., Chapman K.E. Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J. Immunol. 2006, 176:7605-7611.
17. Glezer I., Rivest S. Glucocorticoids: protectors of the brain during innate immune responses. Neuroscientist 2004, 10:538-552.
18. Gold S.M., Raji A., Huitinga I., Wiedemann K., Schulz K.H., Heesen C. Hypothalamo-pituitary-adrenal axis activity predicts disease progression in multiple sclerosis. J. Neuroimmunol. 2005, 165:186-191.
19. Groyer G., Eychenne B., Girard C., Rajkowski K., Schumacher M., Cadepond F. Expression and functional state of the corticosteroid receptors and 11 beta-hydroxysteroid dehydrogenase type 2 in Schwann cells. Endocrinology 2006, 147:4339-4350.
20. Guazzo E.P., Kirkpatrick P.J., Goodyer I.M., Shiers H.M., Herbert J. Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J. Clin. Endocrinol. Metab. 1996, 81:3951-3960.
21. Harbuz M. Neuroendocrine function and chronic inflammatory stress. Exp. Physiol. 2002, 87:519-525.
22. Hildebrand F., Pape H.C., Hoevel P., Krettek C., van Griensven M. The importance of systemic cytokines in the pathogenesis of polymicrobial sepsis and dehydroepiandrosterone treatment in a rodent model. Shock 2003, 20:338-346.
23. Hirst C., Swingler R., Compston D.A., Ben-Shlomo Y., Robertson N.P. Survival and cause of death in multiple sclerosis: a prospective population-based study. J. Neurol. Neurosurg. Psychiatry 2008, 79:1016-1021.
24. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
25. Holub M., Beran O., Dzupova O., Hnykova J., Lacinova Z., Prihodova J., Prochazka B., Helcl M. Cortisol levels in cerebrospinal fluid correlate with severity and bacterial origin of meningitis. Crit. Care 2007, 11:R41.
26. Kim S.B., Hill M., Kwak Y.T., Hampl R., Jo D.H., Morfin R. Neurosteroids: cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. J. Clin. Endocrinol. Metab. 2003, 88:5199-5206.
27. Kipper-Galperin M., Galilly R., Danenberg H.D., Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor alpha and interleukin-6 in astrocytes. Int. J. Dev. Neurosci. 1999, 17:765-775.
28. Kümpfel T., Then Bergh F., Friess E., Uhr M., Yassouridis A., Trenkwalder C., Holsboer F. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology 1999, 70:431-438.
29. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
30. Lassmann H., Brück W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
31. Limone P., Ferrero B., Calvelli P., Del Rizzo P., Rota E., Berardi C., Barberis A.M., Isaia G.C., Durelli L. Hypothalamic-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-beta treatment. Acta Neurol. Scand. 2002, 105:372-377.
32. Michelson D., Stone L., Galliven E., Magiakou M.A., Chrousos G.P., Sternberg E.M., Gold P.W. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J. Clin. Endocrinol. Metab. 1994, 79:848-853.
33. Nair S., Lee Y.H., Lindsay R.S., Walker B.R., Tataranni P.A., Bogardus C., Baier L.J., Permana P.A. 11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 2004, 47:1088-1095.
34. Oliveri R.L., Valentino P., Russo C., Sibilia G., Aguglia U., Bono F., Fera F., Gambardella A., Zappia M., Pardatscher K., Quattrone A. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998, 50:1833-1836.
35. Pelletier G., Luu-The V., Li S., Bujold G., Labrie F. Localization and glucocorticoid regulation of 11beta-hydroxysteroid dehydrogenase type 1 mRNA in the male mouse forebrain. Neuroscience 2007, 145:110-115.
36. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" Ann. Neurol. 2005, 58:840-846.
37. Predine J., Brailly S., Delaporte P., Milgrom E. Protein binding of cortisol in human cerebrospinal fluid. J. Clin. Endocrinol. Metab. 1984, 58:6-11.
38. R Development Core Team R: A Language and Environment for Statistical Computing 2009, R Foundation for Statistical Computing, Vienna, AT.
39. Schmidt M., Weidler C., Naumann H., Anders S., Schölmerich J., Straub R.H. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system?. Arthritis Rheum. 2005, 52:1711-1720.
40. Schumann E.M., Kümpfel T., Then Bergh F., Trenkwalder C., Holsboer F., Auer D.P. Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. Ann. Neurol. 2002, 51:763-767.
41. Seckl J.R. 11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?. Front. Neuroendocrinol. 1997, 18:49-99.
42. Shimojima Y., Matsuda M., Gono T., Ishii W., Tokuda T., Ikeda S. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone. J. Clin. Neurosci. 2006, 13:39-44.
43. Sorensen P.S., Mellgren S.I., Svenningsson A., Elovaara I., Frederiksen J.L., Beiske A.G., Myhr K.M., Sogaard L.V., Olsen I.C., Sandberg-Wollheim M. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009, 8:519-529.
44. Tellez N., Comabella M., Julia E., Rio J., Tintore M., Brieva L., Nos C., Montalban X. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult. Scler. 2006, 12:487-494.
45. Then Bergh F., Kumpfel T., Trenkwalder C., Rupprecht R., Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999, 53:772-777.
46. Thieringer R., Le Grand C.B., Carbin L., Cai T.Q., Wong B., Wright S.D., Hermanowski-Vosatka A. 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 2001, 167:30-35.
47. Tischner D., Reichardt H.M. Glucocorticoids in the control of neuroinflammation. Mol. Cell. Endocrinol. 2007, 275:62-70.
48. VanLandingham J.W., Cekic M., Cutler S., Hoffman S.W., Stein D.G. Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci. Lett. 2007, 425:94-98.
49. Wei T., Lightman S.L. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997, 120(Pt. 6):1067-1076.
50. Ysrraelit M.C., Gaitan M.I., Lopez A.S., Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008, 71:1948-1954.
51. Zhang T.Y., Ding X., Daynes R.A. The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J. Immunol. 2005, 174:879-889.